<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</title><description>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</description><link>https://www.neurologylive.com/news</link><category>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</category><copyright>© 2026 MJH Life Sciences™ and NeurologyLive - Clinical Neurology News and Neurology Expert Insights. All rights reserved.</copyright><lastBuildDate>Sat, 15 Aug 2026 02:51:17 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.neurologylive.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</title><width>144</width><height>47</height><link>https://www.neurologylive.com/news</link><url>https://www.neurologylive.com/logo.webp</url></image><item><title>&lt;![CDATA[CN045 Promotes Oligodendrocyte Maturation, Modest Remyelination in Preclinical MS Study]]&gt;</title><link>https://www.neurologylive.com/view/cn045-promotes-oligodendrocyte-maturation-modest-remyelination-preclinical-ms-study</link><guid isPermaLink="true">https://www.neurologylive.com/view/cn045-promotes-oligodendrocyte-maturation-modest-remyelination-preclinical-ms-study</guid><description>&lt;![CDATA[Experimental small molecule CN045 promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis, supporting further development of the compound as a potential remyelination therapy.]]&gt;</description><pubDate>Fri, 14 Aug 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[NeurologyLive® Friday 5 — August 14, 2026]]&gt;</title><link>https://www.neurologylive.com/view/neurologylive-friday-5-august-14-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/neurologylive-friday-5-august-14-2026</guid><description>&lt;![CDATA[Take 5 minutes to catch up on NeurologyLive®&apos;s highlights from the week ending August 14, 2026. ]]&gt;</description><pubDate>Fri, 14 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[The Future of Blood-Based Biomarkers in Alzheimer Disease]]&gt;</title><link>https://www.neurologylive.com/view/the-future-of-blood-based-biomarkers-alzheimer-disease</link><guid isPermaLink="true">https://www.neurologylive.com/view/the-future-of-blood-based-biomarkers-alzheimer-disease</guid><description>&lt;![CDATA[In the final episode, Yogesh Shah, MD, MPH, FAAFP, details how Alzheimer biomarkers have evolved and why blood-based testing could move the field toward earlier detection, risk reduction, and ultimately prevention.]]&gt;</description><pubDate>Fri, 14 Aug 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[PACAP in Migraine: Bridging Preclinical Studies and Clinical Translation]]&gt;</title><link>https://www.neurologylive.com/view/pacap-in-migraine-bridging-preclinical-studies-clinical-translation</link><guid isPermaLink="true">https://www.neurologylive.com/view/pacap-in-migraine-bridging-preclinical-studies-clinical-translation</guid><description>&lt;![CDATA[Clinician author Kevin Chang, PharmD, writes about PACAP as a distinct, druggable migraine pathway independent of CGRP, offering a promising option for patients who don&apos;t respond to current therapies.]]&gt;</description><pubDate>Fri, 14 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup]]&gt;</title><link>https://www.neurologylive.com/view/fda-approves-tau-pet-tracer-mk-6240-alzheimer-diagnostic-workup</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-approves-tau-pet-tracer-mk-6240-alzheimer-diagnostic-workup</guid><description>&lt;![CDATA[The FDA approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.]]&gt;</description><pubDate>Fri, 14 Aug 2026 12:49:56 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Brain Chat: Stronger Together: Communicating With Care Partners in Chronic Disease]]&gt;</title><link>https://www.neurologylive.com/view/brain-chat-stronger-together-communicating-care-partners-chronic-disease</link><guid isPermaLink="true">https://www.neurologylive.com/view/brain-chat-stronger-together-communicating-care-partners-chronic-disease</guid><description>&lt;![CDATA[Mitzi Joi Williams, MD, is joined by Charnetta Colton Poole, MD, to discuss the challenges of communication between people living with chronic illness and their care partners, including maintaining autonomy, navigating changing roles, and building collaborative relationships through open communication.]]&gt;</description><pubDate>Fri, 14 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones]]&gt;</title><link>https://www.neurologylive.com/view/voyager-advance-2-tau-targeted-alzheimer-therapies-toward-key-clinical-milestones</link><guid isPermaLink="true">https://www.neurologylive.com/view/voyager-advance-2-tau-targeted-alzheimer-therapies-toward-key-clinical-milestones</guid><description>&lt;![CDATA[Voyager Therapeutics is advancing 2 tau-targeted Alzheimer disease therapies toward key clinical milestones expected in the fourth quarter of 2026, including tau PET imaging data for VY7523 and first-in-human dosing for VY1706.]]&gt;</description><pubDate>Thu, 13 Aug 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis]]&gt;</title><link>https://www.neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis</guid><description>&lt;![CDATA[The FDA has cleared Quantum BioPharma&apos;s investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.]]&gt;</description><pubDate>Thu, 13 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[From Fellowship to Practice: Career Advice for Early-Career Neurologists]]&gt;</title><link>https://www.neurologylive.com/view/fellowship-practice-career-advice-early-career-neurologists</link><guid isPermaLink="true">https://www.neurologylive.com/view/fellowship-practice-career-advice-early-career-neurologists</guid><description>&lt;![CDATA[Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.]]&gt;</description><pubDate>Thu, 13 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Safety Considerations for the First Approved Therapy in TK2 Deficiency]]&gt;</title><link>https://www.neurologylive.com/view/safety-considerations-for-the-first-approved-therapy-in-tk2-deficiency</link><guid isPermaLink="true">https://www.neurologylive.com/view/safety-considerations-for-the-first-approved-therapy-in-tk2-deficiency</guid><description>&lt;![CDATA[Neurologist Michio Hirano, MD, reviews the safety profile of doxecitine and doxribtimine, discussing common adverse events, dose management strategies, and practical considerations for monitoring patients with TK2 deficiency.]]&gt;</description><pubDate>Thu, 13 Aug 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[First-Ever Platform Trial for Progressive Supranuclear Palsy Enrolls Its Inaugural Participant]]&gt;</title><link>https://www.neurologylive.com/view/first-ever-platform-trial-progressive-supranuclear-palsy-enrolls-inaugural-participant</link><guid isPermaLink="true">https://www.neurologylive.com/view/first-ever-platform-trial-progressive-supranuclear-palsy-enrolls-inaugural-participant</guid><description>&lt;![CDATA[CurePSP and UCSF announced enrollment of the first participant in the PSP Trial Platform, believed to be the first platform trial ever conducted specifically for progressive supranuclear palsy, designed to test multiple investigational drugs simultaneously.]]&gt;</description><pubDate>Thu, 13 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[How P-tau217 Could Shift the Timing of Alzheimer Care]]&gt;</title><link>https://www.neurologylive.com/view/how-p-tau217-could-shift-the-timing-alzheimer-care</link><guid isPermaLink="true">https://www.neurologylive.com/view/how-p-tau217-could-shift-the-timing-alzheimer-care</guid><description>&lt;![CDATA[Yogesh Shah, MD, MPH, FAAFP, discusses how earlier identification of Alzheimer pathology with P-tau217 could change the patient journey, from treatment opportunities to long-term planning and dementia risk reduction.]]&gt;</description><pubDate>Wed, 12 Aug 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Post Hoc Analysis Shows Fenfluramine Treatment Associated With Sustained Seizure Reductions in LGS]]&gt;</title><link>https://www.neurologylive.com/view/post-hoc-analysis-shows-fenfluramine-associated-sustained-seizure-reductions-lgs</link><guid isPermaLink="true">https://www.neurologylive.com/view/post-hoc-analysis-shows-fenfluramine-associated-sustained-seizure-reductions-lgs</guid><description>&lt;![CDATA[In a recently published phase 3 post hoc analysis, treatment with fenfluramine was associated with early, sustained reductions in fall-related seizures among patients with Lennox-Gastaut syndrome.]]&gt;</description><pubDate>Wed, 12 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Ractigen Completes Phase 2 Enrollment for RAG-17 in SOD1-ALS]]&gt;</title><link>https://www.neurologylive.com/view/ractigen-completes-phase-2-enrollment-for-rag-17-sod1-als</link><guid isPermaLink="true">https://www.neurologylive.com/view/ractigen-completes-phase-2-enrollment-for-rag-17-sod1-als</guid><description>&lt;![CDATA[Ractigen Therapeutics announced completion of enrollment and first dosing across all cohorts of its phase 2 trial of RAG-17, an investigational siRNA therapy for SOD1-mutated ALS, building on phase 1 data recently published in Nature Medicine.]]&gt;</description><pubDate>Wed, 12 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[What Achieving an INCAT Score of 0 or 1 Means for Patients With CIDP]]&gt;</title><link>https://www.neurologylive.com/view/what-achieving-an-incat-score-of-0-or-1-means-for-patients-with-cidp</link><guid isPermaLink="true">https://www.neurologylive.com/view/what-achieving-an-incat-score-of-0-or-1-means-for-patients-with-cidp</guid><description>&lt;![CDATA[For clinicians treating chronic inflammatory demyelinating polyneuropathy, numerical improvements on disability scales ultimately matter only if they translate into better function for patients.]]&gt;</description><pubDate>Wed, 12 Aug 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Addressing the Unmet Needs of Adults With Spinal Muscular Atrophy]]&gt;</title><link>https://www.neurologylive.com/view/addressing-unmet-needs-adults-spinal-muscular-atrophy</link><guid isPermaLink="true">https://www.neurologylive.com/view/addressing-unmet-needs-adults-spinal-muscular-atrophy</guid><description>&lt;![CDATA[Senda Ajroud-Driss, MD, director of the ALS Clinic at Northwestern Medicine, discussed why adults with spinal muscular atrophy continue to need multidisciplinary care and where the evidence still falls short.]]&gt;</description><pubDate>Wed, 12 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Building a Sustainable Care Plan for Adolescents and Adults With Lennox-Gastaut Syndrome: Cynthia Keator, MD]]&gt;</title><link>https://www.neurologylive.com/view/building-sustainable-care-plan-for-adolescents-adults-with-lennox-gastaut-syndrome-cynthia-keator</link><guid isPermaLink="true">https://www.neurologylive.com/view/building-sustainable-care-plan-for-adolescents-adults-with-lennox-gastaut-syndrome-cynthia-keator</guid><description>&lt;![CDATA[The director of neurology at Cook Children&apos;s Hospital discusses overlooked challenges in transitioning patients with Lennox-Gastaut syndrome from pediatric to adult care, including insurance changes, mobility concerns, and long-term care planning. [WATCH TIME: 3 minutes]]]&gt;</description><pubDate>Tue, 11 Aug 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Bridging Pediatric and Adult Care in Spinal Muscular Atrophy]]&gt;</title><link>https://www.neurologylive.com/view/bridging-pediatric-and-adult-care-spinal-muscular-atrophy</link><guid isPermaLink="true">https://www.neurologylive.com/view/bridging-pediatric-and-adult-care-spinal-muscular-atrophy</guid><description>&lt;![CDATA[Divya Jayaraman, MD, PhD, a pediatric neuromuscular specialist at Columbia University Irving Medical Center, discussed the comparative evidence gaps in spinal muscular atrophy and the difficulty of moving patients into adult care.]]&gt;</description><pubDate>Tue, 11 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Prodromal MSA Criteria, Validated: What the New Data Mean for Research and Clinical Practice]]&gt;</title><link>https://www.neurologylive.com/view/prodromal-msa-criteria-validated-what-new-data-mean-research-clinical-practice</link><guid isPermaLink="true">https://www.neurologylive.com/view/prodromal-msa-criteria-validated-what-new-data-mean-research-clinical-practice</guid><description>&lt;![CDATA[Horacio Kaufmann, MD, Director of the Dysautonomia Center at NYU Langone, discusses the prospective validation of prodromal MSA criteria, how olfactory testing can sharpen specificity, and how close the field is to biomarker-driven early diagnosis.]]&gt;</description><pubDate>Tue, 11 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Tanruprubart Shows Rapid Responses in First FORWARD Cohort for Guillain-Barre Syndrome]]&gt;</title><link>https://www.neurologylive.com/view/tanruprubart-shows-rapid-responses-first-forward-cohort-guillain-barre-syndrome</link><guid isPermaLink="true">https://www.neurologylive.com/view/tanruprubart-shows-rapid-responses-first-forward-cohort-guillain-barre-syndrome</guid><description>&lt;![CDATA[Annexon reported that all 10 patients in the first US and European cohort of its open-label FORWARD study showed rapid, clinically meaningful improvement in strength within days of a single tanruprubart infusion for Guillain-Barré syndrome.]]&gt;</description><pubDate>Tue, 11 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Building a Multidisciplinary SMA Clinic: Lessons From 2 Decades of Practice]]&gt;</title><link>https://www.neurologylive.com/view/building-multidisciplinary-sma-clinic-lessons-from-2-decades-practice</link><guid isPermaLink="true">https://www.neurologylive.com/view/building-multidisciplinary-sma-clinic-lessons-from-2-decades-practice</guid><description>&lt;![CDATA[Sandeep Rana, MD, director of the ALS Center at the Allegheny Health Network Neuroscience Institute, discussed how multidisciplinary clinics are assembled and what still limits access to coordinated care in spinal muscular atrophy.]]&gt;</description><pubDate>Mon, 10 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Coordinating Multidisciplinary SMA Care in an Expanding Treatment Landscape]]&gt;</title><link>https://www.neurologylive.com/view/coordinating-multidisciplinary-sma-care-expanding-treatment-landscape</link><guid isPermaLink="true">https://www.neurologylive.com/view/coordinating-multidisciplinary-sma-care-expanding-treatment-landscape</guid><description>&lt;![CDATA[Divya Jayaraman, MD, PhD, a pediatric neuromuscular specialist at Columbia University Irving Medical Center, discussed how multidisciplinary care teams in spinal muscular atrophy are adapting to a growing number of treatment options.]]&gt;</description><pubDate>Mon, 10 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[This Week on NeurologyLive® — August 10, 2026]]&gt;</title><link>https://www.neurologylive.com/view/this-week-on-neurologylive-august-10-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/this-week-on-neurologylive-august-10-2026</guid><description>&lt;![CDATA[Here&apos;s some of what is coming soon to NeurologyLive® this week. ]]&gt;</description><pubDate>Mon, 10 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Approves Oveporexton for NT1, Grants RMAT Designation to Sasineprocel in PD, Emerging Literature in Spinal Muscular Atrophy ]]&gt;</title><link>https://www.neurologylive.com/view/fda-approves-oveporexton-nt1-grants-rmat-designation-sasineprocel-pd-emerging-literature-spinal-muscular-atrophy</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-approves-oveporexton-nt1-grants-rmat-designation-sasineprocel-pd-emerging-literature-spinal-muscular-atrophy</guid><description>&lt;![CDATA[Neurology News Network for the week ending August 8th, 2026. [WATCH TIME: 4 minutes]]]&gt;</description><pubDate>Sun, 09 Aug 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[NeurologyLive® Brain Games: August 9, 2026]]&gt;</title><link>https://www.neurologylive.com/view/neurologylive-brain-games-august-9-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/neurologylive-brain-games-august-9-2026</guid><description>&lt;![CDATA[Test your neurology knowledge with NeurologyLive®&apos;s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week&apos;s topic is Spinal Muscular Atrophy!]]&gt;</description><pubDate>Sun, 09 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Long-Term Follow-Up Shows Safety Signal for OXB-102 Gene Therapy in Parkinson Disease]]&gt;</title><link>https://www.neurologylive.com/view/long-term-follow-up-shows-safety-signal-oxb-102-gene-therapy-parkinsons</link><guid isPermaLink="true">https://www.neurologylive.com/view/long-term-follow-up-shows-safety-signal-oxb-102-gene-therapy-parkinsons</guid><description>&lt;![CDATA[Investigators independently tracked the 6 patients treated in a Parkinson disease gene therapy trial that was abandoned mid-study after its sponsor became insolvent, finding a reassuring safety profile and mixed signals of motor benefit through up to 3 years.]]&gt;</description><pubDate>Sat, 08 Aug 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Pediatrics to Adulthood: What the LGS Care Transition is Still Getting Wrong]]&gt;</title><link>https://www.neurologylive.com/view/pediatrics-to-adulthood-what-lgs-care-transition-still-getting-wrong</link><guid isPermaLink="true">https://www.neurologylive.com/view/pediatrics-to-adulthood-what-lgs-care-transition-still-getting-wrong</guid><description>&lt;![CDATA[Cynthia Keator, MD, director of neurology at Cook Children&apos;s Hospital, shares her perspective on building longitudinal Lennox-Gastaut syndrome care plans, navigating the pediatric-to-adult transition, and what the field needs to do better for patients and families.]]&gt;</description><pubDate>Fri, 07 Aug 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[NeurologyLive® Friday 5 — August 7, 2026]]&gt;</title><link>https://www.neurologylive.com/view/neurologylive-friday-5-august-7-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/neurologylive-friday-5-august-7-2026</guid><description>&lt;![CDATA[Take 5 minutes to catch up on NeurologyLive®&apos;s highlights from the week ending August 7, 2026. ]]&gt;</description><pubDate>Fri, 07 Aug 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Bezisterim Shows Improvements in Motor, Nonmotor Symptoms in Phase 2 SUNRISE-PD Trial ]]&gt;</title><link>https://www.neurologylive.com/view/bezisterim-shows-improvements-motor-nonmotor-symptoms-phase-2-sunrise-pd-trial</link><guid isPermaLink="true">https://www.neurologylive.com/view/bezisterim-shows-improvements-motor-nonmotor-symptoms-phase-2-sunrise-pd-trial</guid><description>&lt;![CDATA[Topline findings from the Phase 2 SUNRISE-PD study showed statistically significant improvements in clinical measures, inflammatory biomarkers, and exploratory neurodegeneration markers among patients with early Parkinson disease treated with bezisterim. ]]&gt;</description><pubDate>Fri, 07 Aug 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Episode 172: Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters]]&gt;</title><link>https://www.neurologylive.com/view/episode-172-sma-awareness-month-why-multidisciplinary-care-matters</link><guid isPermaLink="true">https://www.neurologylive.com/view/episode-172-sma-awareness-month-why-multidisciplinary-care-matters</guid><description>&lt;![CDATA[Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sandeep Rana, MD. [LISTEN TIME: 15 minutes]]]&gt;</description><pubDate>Fri, 07 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item></channel></rss>